Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 55Recurrence 10Neoplasms, Plasma Cell 3Smoldering Multiple Myeloma 2Hematologic Neoplasms 2Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 49Melphalan 29Cyclophosphamide 24Bortezomib 23Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5birtamimab 5auricularum 5Whole-Body Irradiation 5Thalidomide 5Mycophenolic Acid 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Busulfan 4sargramostim 3miridesap 3isatuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoglobulin Light-chain Amyloidosis × elotuzumab × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡